Scientific exchange · Dr. Farah Fischer

17 Jul 2026 · In person · Dr. Farah Fischer, MD Anderson Cancer Center · MSL James Whitfield · Lumeva

ReviewedVeeva CRMENG-0181—

Capture insight from this engagement

Location: MD Anderson Cancer Center
Therapeutic area: Neurology
Country: United States
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Lumeva (lumevarin)

Topics discussed

Real-world persistence
Dosing in hepatic impairment
Switching between CGRP agents

Scientific content used

Chronic migraine scientific platform
LMV persistence data summary

Questions raised

Any data in patients with medication-overuse headache?

Notes

Scientific exchange with primary care physician at MD Anderson Cancer Center. Discussed real-world persistence, dosing in hepatic impairment, switching between cgrp agents.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Invite to advisory board

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 3
Depth of exchange: 4
Actionability: 2

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0181

Audit history (0)

All create, update and approval events for this record

No audit events in sample data